Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX

Tema ETFs LLC acquired a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 55,384 shares of the company’s stock, valued at approximately $1,731,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TNGX. Global Retirement Partners LLC bought a new position in shares of Tango Therapeutics during the fourth quarter valued at $35,000. Dynamic Technology Lab Private Ltd boosted its stake in shares of Tango Therapeutics by 139.7% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after purchasing an additional 15,037 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Tango Therapeutics by 30.7% in the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new stake in shares of Tango Therapeutics in the 4th quarter worth about $40,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Tango Therapeutics by 148,800.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock worth $40,000 after purchasing an additional 4,464 shares in the last quarter. 78.99% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the transaction, the insider owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. This represents a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 6.50% of the company’s stock.

Tango Therapeutics Trading Down 2.9%

Tango Therapeutics stock opened at $25.58 on Thursday. Tango Therapeutics, Inc. has a 1 year low of $6.25 and a 1 year high of $34.39. The company has a market cap of $3.70 billion, a PE ratio of -30.09 and a beta of 1.16. The company’s 50-day moving average is $28.74 and its two-hundred day moving average is $22.12.

Tango Therapeutics (NASDAQ:TNGX) last issued its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Research analysts forecast that Tango Therapeutics, Inc. will post -1.27 EPS for the current year.

Analysts Set New Price Targets

TNGX has been the subject of a number of research analyst reports. Mizuho lifted their target price on shares of Tango Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Canaccord Genuity Group raised their price target on Tango Therapeutics from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, June 29th. UBS Group set a $55.00 price target on Tango Therapeutics in a report on Thursday, May 14th. B. Riley Financial reiterated a “buy” rating on shares of Tango Therapeutics in a research report on Monday, June 8th. Finally, Leerink Partners boosted their price objective on Tango Therapeutics from $55.00 to $69.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Tango Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $43.31.

Tango Therapeutics Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.